Metformin, Liraglutide, Orlistat, and Phentermine for Childhood Obesity and Blood Lipids: A Systematic Review and Meta-Analysis
Abstract
Review question / Objective: Population: Children and adolescents diagnosed with obesity (Defined as being no older than 18 years of age and having a BMI above the 95th percentile for sex and age;).No l i m i t a t i o n o f l o c a t i o n , a n d g e n d e r.Intervention: one medicine of Orlistat, Phentermine, Liraglutide, and Metformin.Comparator: Placebo or Dietary control.We'll only consider random controlled trials.The other types of studies will be excluded such as animal studies, reviews, case reports, non-controlled trials, and quasi-RCTs.Outcomes: Primary outcome: BMI or body mass.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.